- Home
- EYPT vs WGO Comparison
EYPT vs WGO Comparison
Compare EYPT & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | WGO |
|---|---|---|
| Founded | 1987 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Homebuilding |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EYPT | WGO |
|---|---|---|
| Price | $18.29 | $38.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $28.75 | ★ $43.36 |
| AVG Volume (30 Days) | ★ 1.6M | 432.0K |
| Earning Date | 03-23-2026 | 03-30-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | N/A | ★ 106.82 |
| EPS | N/A | ★ 0.19 |
| Revenue | $7,539,000.00 | ★ $1,985,674,000.00 |
| Revenue This Year | N/A | $5.64 |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | $209.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $28.29 |
| 52 Week High | $19.11 | $50.16 |
Technical Indicators
Market Signals| Indicator | EYPT | WGO |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 26.16 |
| Support Level | $11.88 | $29.26 |
| Resistance Level | $19.06 | $41.87 |
| Average True Range (ATR) | 1.27 | 1.87 |
| MACD | 0.54 | -1.02 |
| Stochastic Oscillator | 90.58 | 15.00 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About WGO Winnebago Industries Inc.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.